AZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewThe FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, Share XAZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewhttps://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/
NICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBCNICE has said Roche’s Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a Share XNICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBChttps://pharmaphorum.com/news/nice-says-no-to-regular-nhs-funding-for-roches-tecentriq-in-tnbc/
Merck & Co hopes for foothold in early TNBC after Keytruda trial winMerck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold Share XMerck & Co hopes for foothold in early TNBC after Keytruda trial winhttps://pharmaphorum.com/news/merck-co-hopes-for-foothold-in-early-tnbc/
Tecentriq beats rivals to EU breast cancer marketRoche has claimed approval in Europe for Tecentriq as a therapy for hard-to-treat triple-negative breast cancer (TNBC), ahead Share XTecentriq beats rivals to EU breast cancer markethttps://pharmaphorum.com/news/tecentriq-beats-rivals-to-eu-breast-cancer-market/
Study resurrects Merck’s hopes for Keytruda in breast cancerJust a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast Share XStudy resurrects Merck’s hopes for Keytruda in breast cancerhttps://pharmaphorum.com/news/study-resurrects-mercks-hopes-for-keytruda-in-breast-cancer/
NICE changes its mind on Novartis’ Kisqali for breast cancerNICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England Share XNICE changes its mind on Novartis’ Kisqali for breast cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-kisqali-for-breast-cancer/
Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
Roche closes on EU approval for Tecentriq in breast cancerRoche is heading for EU approval of Tecentriq as first-line therapy for triple-negative breast cancer (TNBC), ahead of Share XRoche closes on EU approval for Tecentriq in breast cancerhttps://pharmaphorum.com/news/roche-closes-on-eu-approval-for-tecentriq-in-breast-cancer/
EU safety experts begin review of leuprorelin-containing drugsEuropean safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer Share XEU safety experts begin review of leuprorelin-containing drugshttps://pharmaphorum.com/news/eu-safety-experts-begin-review-of-leuprorelin-containing-drugs/
